60 Assessing hyaluronidase-facilitated subcutaneous immunoglobulin 20% (fSCIG 20%) pharmacokinetics, safety and tolerability in primary immunodeficiency diseases: phase 2/3 study design

Richard LWasserman(ENT and Allergy), Zhaoyang Li(Yangpu Hospital of Tongji University), Colin Anderson‐Smits(Takeda (United States)), Alexander Bauer(Takeda (Austria)), Helen L. Leavis(University Medical Center Utrecht), Liang-Hui Chu(Takeda (United States)), Paz Carrasco(Baxalta (United States)), András Nagy(University of Szeged), Barbara McCoy(Baxalta (United States)), Immanuel Freedman(Takeda (United States))
Clinical Immunology
April 23, 2024
10.1016/j.clim.2024.110002
Cited by 0

Related Papers

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report
|medRxiv|2021|137
A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms
|Cardiovascular Drugs and Therapy|2024|38
Selected Abstracts from the 12th Annual Meeting of the Clinical Immunology Society: 2021 Virtual Annual Meeting: Immune Deficiency and Dysregulation North American Conference
|Journal of Clinical Immunology|2021|28
Chemical Constituents and Hypoglycemic Mechanisms of Dendrobium nobile in Treatment of Type 2 Diabetic Rats by UPLC-ESI-Q-Orbitrap, Network Pharmacology and In Vivo Experimental Verification
|Molecules|2023|23
Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial
|Thorax|2025|12